Department of Neurosurgery, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Neurocrit Care. 2024 Oct;41(2):498-510. doi: 10.1007/s12028-024-01959-7. Epub 2024 Mar 14.
Volatile sedation is still used with caution in patients with acute brain injury because of safety concerns. We analyzed the effects of sevoflurane sedation on systemic and cerebral parameters measured by multimodal neuromonitoring in patients after aneurysmal subarachnoid hemorrhage (aSAH) with normal baseline intracranial pressure (ICP).
In this prospective observational study, we analyzed a 12-h period before and after the switch from intravenous to volatile sedation with sevoflurane using the Sedaconda Anesthetic Conserving Device with a target Richmond Agitation Sedation Scale score of - 5 to - 4. ICP, cerebral perfusion pressure (CPP), brain tissue oxygenation (PBrO), metabolic values of cerebral microdialysis, systemic cardiopulmonary parameters, and the administered drugs before and after the sedation switch were analyzed.
We included 19 patients with a median age of 61 years (range 46-78 years), 74% of whom presented with World Federation of Neurosurgical Societies grade 4 or 5 aSAH. We observed no significant changes in the mean ICP (9.3 ± 4.2 vs. 9.7 ± 4.2 mm Hg), PBrO (31.0 ± 13.2 vs. 32.2 ± 12.4 mm Hg), cerebral lactate (5.0 ± 2.2 vs. 5.0 ± 1.9 mmol/L), pyruvate (136.6 ± 55.9 vs. 134.1 ± 53.6 µmol/L), and lactate/pyruvate ratio (37.4 ± 8.7 vs. 39.8 ± 9.2) after the sedation switch to sevoflurane. We found a significant decrease in mean arterial pressure (MAP) (88.6 ± 7.6 vs. 86.3 ± 5.8 mm Hg) and CPP (78.8 ± 8.5 vs. 76.6 ± 6.6 mm Hg) after the initiation of sevoflurane, but the decrease was still within the physiological range requiring no additional hemodynamic support.
Sevoflurane appears to be a feasible alternative to intravenous sedation in patients with aSAH without intracranial hypertension, as our study did not show negative effects on ICP, cerebral oxygenation, or brain metabolism. Nevertheless, the risk of a decrease of MAP leading to a consecutive CPP decrease should be considered.
由于安全性方面的考虑,挥发性镇静剂在急性脑损伤患者中仍谨慎使用。我们分析了七氟醚镇静对蛛网膜下腔出血(aSAH)后颅内压正常的患者进行多模态神经监测时系统和大脑参数的影响。
在这项前瞻性观察研究中,我们分析了从静脉镇静切换到七氟醚镇静的 12 小时期间,使用 Sedaconda 麻醉保存装置,目标 Richmond 激动镇静量表评分为-5 至-4。分析了镇静切换前后的颅内压(ICP)、脑灌注压(CPP)、脑组织氧合(PBrO)、脑微透析的代谢值、系统心肺参数以及镇静前后的药物使用情况。
我们纳入了 19 名中位年龄 61 岁(范围 46-78 岁)的患者,其中 74%的患者为世界神经外科学联合会 4 级或 5 级 aSAH。我们观察到 ICP(9.3±4.2 与 9.7±4.2mmHg)、PBrO(31.0±13.2 与 32.2±12.4mmHg)、脑乳酸(5.0±2.2 与 5.0±1.9mmol/L)、丙酮酸(136.6±55.9 与 134.1±53.6µmol/L)和乳酸/丙酮酸比值(37.4±8.7 与 39.8±9.2)在镇静切换到七氟醚后没有显著变化。我们发现镇静切换到七氟醚后平均动脉压(MAP)(88.6±7.6 与 86.3±5.8mmHg)和 CPP(78.8±8.5 与 76.6±6.6mmHg)显著降低,但降低仍在生理范围内,无需额外的血流动力学支持。
七氟醚似乎是颅内压正常的 aSAH 患者替代静脉镇静的可行选择,因为我们的研究没有显示对 ICP、脑氧合或脑代谢产生负面影响。然而,应考虑 MAP 降低导致 CPP 降低的风险。